Results 241 to 250 of about 252,929 (281)
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin +11 more
wiley +1 more source
Autism Spectrum Disorder and Co-occurring Substance Use Disorder – A Systematic Review
Espen Ajo Arnevik +1 more
doaj
Prevalence of substance use disorder in individuals with attention deficit/hyperactivity disorder: associations with sex and psychiatric comorbidity. [PDF]
Moldekleiv CD +6 more
europepmc +1 more source
Understanding barriers and facilitators of inter-organizational dynamics in addressing substance use disorder among pregnant and parenting women. [PDF]
Choi S +7 more
europepmc +1 more source
Competency Acquisition of WHO ASSIST for Assessment of Substance Use Disorder in Medical Curriculum of Undergraduates. [PDF]
Pundhir A, Swami MK, Basu A.
europepmc +1 more source
Examining Vaping Policies in Substance Use Disorder Treatment Facilities. [PDF]
Ware OD +3 more
europepmc +1 more source
Low-Dose Clozapine Reduces Aggression in Violent Substance Use Disorder Patients at a Secure Rehabilitation Center. [PDF]
Yousuf SM +4 more
europepmc +1 more source

